Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation/Dose Expansion Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma

NCT04782609 is registered in ClinicalTrials.gov with Samus Therapeutics, Inc. as lead sponsor.

NCT NCT04782609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04782609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation/Dose Expansion Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
Lead sponsor
Samus Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 27, 2021
Completion date
November 4, 2022
Enrollment
7 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma surgery, grade 3 isocitrate dehydrogenase (idh) wildtype astrocytoma, grade 3 or 4 astrocytoma, recurrent glioblastoma multiforme (gbm)